Incidence of Thromboembolic Events in Oncology Patients Receiving Intraoperative Tranexamic Acid During Orthopedic Surgery: A Retrospective Review at a Comprehensive Cancer Center.

Authors

Robert S Ackerman
Michael Hirschi
Nathaniel Trona
David M Joyce
Trip Evans
Sephalie Y Patel

Publication/Presentation Date

1-15-2020

Abstract

Despite an abundance of evidence, routine perioperative antifibrinolytics have been avoided in oncology patients due to concern of thrombosis when given to patients with a preexisting hypercoagulable state. We present a retrospective review of 104 patients with an oncologic diagnosis who received intraoperative tranexamic acid during orthopedic surgery. Overall, complication rates were low, including deep vein thrombosis (1.0%), pulmonary embolism (4.8%), stroke (0%), and myocardial infarction (0%). This preliminary evidence shows that antifibrinolytics such as tranexamic acid may be considered perioperatively in oncology patients without increased risk of thromboembolic events; however, further prospective trials are encouraged.

Volume

14

Issue

2

First Page

63

Last Page

66

ISSN

2575-3126

Published In/Presented At

Ackerman, R. S., Hirschi, M., Trona, N., Joyce, D. M., Evans, T., & Patel, S. Y. (2020). Incidence of Thromboembolic Events in Oncology Patients Receiving Intraoperative Tranexamic Acid During Orthopedic Surgery: A Retrospective Review at a Comprehensive Cancer Center. A&A practice, 14(2), 63–66. https://doi.org/10.1213/XAA.0000000000001129

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

31703004

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article